Alpha Tau Medical Ltd · NASDAQ:DRTS
Alpha Tau Medical — SPAC Merger (January 2022)
35 slides from Alpha Tau Medical's SPAC merger presentation, Jan 12, 2022
Slide 1: Company Overview
AlphetAU Company Overview January 2022
Slide 2: Disclaimer
Disclaimer This presentation (together with oral statements made in connection herewith, the Presentation ) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the Business Combination ) between Healthcare
Slide 3: Disclaimer (cont'd)
Disclaimer (cont’d) Use of Projections This Presentation contains projected financial information with respect to Alpha Tau. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicati
Slide 4: Alpha Tau – Key Investment Highlights
Confidential Alpha Tau – Key Investment Highlights Proprietary Alpha DaRT designed to safely deliver alpha radiation with localized precision in solid tumors, sparing 1 surrounding healthy tissue Broad potential and preclinical evidence supporting evaluation across various solid tumors (skin, pancre
Slide 5: Therapeutic Focus
Confidential Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT would be evaluated • Solid tumo
Slide 6: Development Pipeline
Confidential Development Pipeline • Our clinical trial strategy involves progressing our lead program (superficial tumors), particularly in the US, and conducting feasibility studies in other tumors to evaluate the Alpha DaRT in tumors of high unmet need or metastatic disease • FDA Breakthrough Devi
Slide 7: Types of Radioactive Decay
Confidential Types of Radioactive Decay Due to the mass of the alpha particle, in comparison to beta particle, alpha has a low penetration power. This means that the outside layer of the human skin, for example, can block these particles. 7
Slide 8: Potent Alpha Radiation: Extensively Damages the DNA
Confidential Potent Alpha Radiation: Extensively Damages the DNA Local radiation therapy with gamma or beta radiation is a mainstay of cancer treatment, but requires high local dose to be effective, as it primarily relies on single-strand breaks in a process relying on oxygen. Alpha radiation can be
Slide 9: Alpha Radiation is Focal - Short Range Limits Clinical Use
Confidential Alpha Radiation is Focal - Short Range Limits Clinical Use Whereas beta and gamma radiation can penetrate tissue with sufficient range to facilitate tumor coverage (while risking damage to healthy tissue), alpha radiation has short range in tissue (<100 μm), which limits its clinical us
Slide 10: Mechanism of Action of the Alpha DaRT Technology
Confidential Mechanism of Action of the Alpha DaRT Technology 224 Ra Decay Chain Alpha DaRT leverages the innate decay chain of Radium-224 The decay chain of Radium-224 includes four alpha particles Radium-224 has a half-life of ~3.7 days, while the remaining decay chain has a total half-life of app
Slide 11: Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy
Confidential Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy https://www.youtube.com/watch?v=nwfzJHm0fTQ 11
Slide 12: Alpha DaRT Has a Unique Potential to Preserve Healthy Tissues
Confidential Alpha DaRT Has a Unique Potential to Preserve Healthy Tissues Alpha DaRT is unique in its potential to deliver a high The range of the Alpha DaRT was observed to be dose of radiation in a very conformal form, with sharp meaningfully more extensive in tumor tissue than in dose drop-off o
Slide 13: Alpha DaRT Source Placement
Confidential Alpha DaRT Source Placement Through a series of Alpha DaRT injections to the tumor, spread a few millimeters apart, a clinician can potentially deliver alpha radiation to the full geometry of the tumor while taking care to avoid sensitive healthy tissue around the tumor < 5 mm between s
Slide 14: Intra-tumoral Delivery Methods
Confidential Intra-tumoral Delivery Methods We Have a Total of Seven Applicators Which Have Been Developed for a Range of Potential Uses to Accommodate for: Treatment Delivery Duration of Tumor Location Method Implantation Our Applicators Allow Us Flexibility to Deliver Alpha DaRTs Into Both Superfi
Slide 15: Response Observed in All Tested Solid Tumors in Preclinical Studies
Confidential Response Observed in All Tested Solid Tumors in Preclinical Studies 18 Published Preclinical Studies in Peer-Reviewed Journals Across a variety of tumor types, we have not observed resistance to the radiation delivered by the Alpha DaRT Squamous Cell Carcinoma Colon Carcinoma Lung Adeno
Slide 16: Observed Cancer-Specific Immune Protection (1/2)
Confidential Observed Cancer-Specific Immune Protection (1/2) In challenging mice 4 months after treatment, those previously treated by the Alpha DaRT displayed a meaningful retained protection against regrowth of the same tumor type, as compared to the two control groups 1 Tumor Re-Inoculation afte
Slide 17: Observed Cancer-Specific Immune Protection (2/2)
Confidential Observed Cancer-Specific Immune Protection (2/2) This activity was then shown to be tumor-specific – the challenge only resisted regrowth of the same tumor line. It was also shown to be transferrable via the transfer of splenocytes 2 2 Tumor Re-Inoculation Immune-Memory Transfer Tumor T
Slide 18: Alpha DaRT Elicits Effect from anti-PD1 in SCC Mouse Model
Confidential Alpha DaRT Elicits Effect from anti-PD1 in SCC Mouse Model (SQ2) While mice with the SQ2 squamous cell carcinoma model showed little to no effect when treated with a murine anti-PD1 agent, the observed effect was larger for the combination with Alpha DaRT than for Alpha DaRT on its own
Slide 19: Alpha DaRT Increases Infiltration of CD3+ T-cells Into the Tumor
Confidential Alpha DaRT Increases Infiltration of CD3+ T-cells Into the Tumor The combination of Alpha DaRT with anti-PD1 demonstrates the highest level of TILs in mice with SQ2 SCC tumors, potentially indicating an ability to potentiate the checkpoint blockade TILs in SQ2 tumors anti PD-1 Alpha DaR
Slide 20: Outline of Our First Clinical Study: Skin / Head & Neck SCC
Confidential Outline of Our First Clinical Study: Skin / Head & Neck SCC Trial Sites: Israel, Italy Primary objective: Evaluate feasibility & safety Secondary objective: Evaluate initial tumor response & local progression-free survival Timeline and Key Eligibility Criteria Treatment & Procedure Foll
Slide 21: Skin / Head & Neck SCC Study Results
Confidential Skin / Head & Neck SCC Study Results 100% overall Responses Well tolerated; Durable response observed no systemic responses rate within days toxicity observed observed Baseline Disease Characteristics Efficacy Results CR Durability (~7 months) 22.7% Overall Response Effective against ra
Slide 22: AP-02 Complete Response
Confidential AP-02 Complete Response Age 80 Applicators used 6 Previous treatments Radiation, Surgery Alpha DaRT sources inserted 10 3 Tumor initial volume [cm ] 1.4 Total activity [µCi] 20 Before Planning After During 21/03/2017 21/03/2017 01/06/2017 22
Slide 23: AP-022 Complete Response
Confidential AP-022 Complete Response Age 68 Applicators used 12 Previous treatments None Alpha DaRT sources inserted 24 3 Tumor initial volume [cm ] 2.8 Total activity [µCi] 48 During Before After During 30/08/2018 27/08/2018 30/08/2018 30/09/2018 23
Slide 24: AP-024 Complete Response
Confidential AP-024 Complete Response Age 61 Applicators used 8 Previous treatments None Alpha DaRT sources inserted 11 3 Tumor initial volume [cm ] 0.6 Total activity [µCi] 22 Before During During After 13/11/2018 13/11/2018 13/11/2018 29/11/2018 24
Slide 25: Alpha DaRT Treatment was Well Tolerated
Confidential Alpha DaRT Treatment was Well Tolerated No systemic toxicities and minimal (< grade 2) local toxicities observed to date Incidence (%) Severity Grade Acute Local Targeted treatment Toxicity 1 2 3 Designed to spare neighboring healthy tissue Administration 11 (41%) 9 (33%) 0 (0%) site er
Slide 26: Potential Systemic Immune Effect Observed in One Patient
Confidential Potential Systemic Immune Effect Observed in One Patient Where a Second, Untreated Lesion Manifested CR Complete Response + Potential Systemic Immune Effect Treated Tumor Untreated Tumors Before After Before After 30-Nov-17 29-Dec-17 30-Nov-17 29-Dec-17 26
Slide 27: U.S. Pilot Feasibility Study
Confidential U.S. Pilot Feasibility Study • FDA Breakthrough Device Designation received in June 2021 • Study results announced in January 2022: At 12 weeks, 100% complete response rate seen across all tested tumors, with no product-related SAEs Locations 5 centers in the US, led by Memorial Sloan K
Slide 28: Applicable Market Size – Estimates of Annual Incidence Data
Confidential Applicable Market Size – Estimates of Annual Incidence Data SCC / H&N Annual Incidence US Incidence: ~1 million US Applicable Mkt. Size Surgery Canada Recurrence, China 17,500 Surgery, Europe 4.5%, 40,500 133,500 1L: 100,000 900,000, 90% 550,000 US Japan Non-Surgery, 2L: 57,500 1,000,00
Slide 29: Simple Radioactive Supply Chain
Confidential S Sim imp pl le e R Ra ad dio ioa ac ct ti iv ve e S Su up pp pl ly y C Ch ha ain in Delivery does not require any special handling and simple planning ensures on-time arrival Alpha DaRT is shipped in Excepted Packages (low levels of radioactivity), Alpha DaRT Radioactive Decay and can
Slide 30: Global Manufacturing Facilities
Confidential Global Manufacturing Facilities For efficient commercial operations, we look to establish manufacturing operations in multiple regions of the world, to enable relatively short shipping times to our core markets Jerusalem (~400,000 sources per year – Ramping Up) Lawrence, Massachusetts (
Slide 31: The Alpha Tau Executive Team
Confidential The Alpha Tau Executive Team Strong management team with years of experience across the scientific and medical device space Uzi Sofer Raphi Levy Prof. Itzhak Kelson Prof. Yona Robert Den, MD Amnon Gat Ronen Segal CEO & Chairman Chief Financial Chief Physics Keisari Chief Medical Chief O
Slide 32: Board of Directors
Confidential Board of Directors Diverse mix of cancer therapeutic, medical device and financial expertise providing value-added oversight and guidance to corporate leadership Uzi Sofer Michael Morry Blumenfeld Meir Jakobsohn Alan Adler Gary Leibler Peter Melnyk CEO & Chairman Avruch Director Directo
Slide 33: Continued Track Record of Execution
Confidential Continued Track Record of Execution Completion First patient Radioactive Provisional Israeli MoH Breakthrough 100% CR rate of treated in license for Israeli MoH and approval Device in US pilot enrollment combination Jerusalem IRB approvals for prostate Designation for study in US pilot
Slide 34: Anticipated Milestones
Confidential Anticipated Milestones Geography Indication 1H 2022 2H 2022 1H 2023 Skin Cancers Completion of multi-center Initiation of multi-center pivotal trial (United States) pivotal trial North America Pancreatic Cancer (Canada) First patient in feasibility Interim read-out of feasibility trial
Slide 35: Saving Lives Globally
Confidential Saving Lives Globally 35